Want to see KLYG full AI Analyst Report?
KLYG Stock Chart & Stats
$0.12
>-$0.01(-1.86%)
At close: 4:00 PM EST
$0.12
>-$0.01(-1.86%)
Day’s Range― - ―
52-Week Range$0.05 - $0.30
Previous CloseN/A
Volume5.00K
Average Volume (3M)23.14K
Market Cap
$7.17M
Enterprise Value$7.73
Total Cash (Recent Filing)$163.33K
Total Debt (Recent Filing)$384.66K
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding50,123,430
10 Day Avg. Volume41,753
30 Day Avg. Volume23,144
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)7.17
Price to Sales (P/S)1.91
P/FCF Ratio-30.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin StrengthSustained ~76% gross margins indicate durable pricing power or a high-value product mix in medical devices. High margins provide structural cushion for operating expenses, enabling the firm to invest in R&D or commercialization while requiring less incremental revenue to reach profitability over the medium term.
Revenue Growth TrendConsistent top-line growth near the high-teens demonstrates ongoing market adoption and commercial traction. Over 2–6 months this trend supports scalable revenue opportunity and the potential to leverage fixed costs, helping the company convert margin advantages into improving operating leverage.
Improving Cash GenerationThe reversal to positive operating and free cash flow shows the business can generate internal funding, reducing reliance on external financing. Even modest positive cash generation improves runway and gives management more flexibility to prioritize profitable growth initiatives and capex over the medium term.
Bears Say
Persistent Net Losses / Negative ROEOngoing net losses and negative return on equity mean the company’s capital base is not yet producing sustainable profits. This limits shareholder returns, may necessitate dilution or additional funding, and constrains the firm’s ability to self-finance expansion without external capital over the medium term.
Cash Flow VolatilityLarge swings in operating and free cash flow create execution and planning risk: management may struggle to fund consistent R&D, regulatory activities, or production scale without backup financing. Volatility increases the likelihood of periodic external capital raises, diluting long-term returns.
Small Operating ScaleA headcount of nine signals limited internal capacity for commercialization, regulatory compliance, and scaling manufacturing in the medical‑device sector. Small scale heightens execution risk, dependence on key personnel, and increases the need for partnerships or hires to sustain durable growth and margins.
KLYG FAQ
What was Kelyniam Global Inc’s price range in the past 12 months?
Kelyniam Global Inc lowest stock price was $0.05 and its highest was $0.30 in the past 12 months.
What is Kelyniam Global Inc’s market cap?
Kelyniam Global Inc’s market cap is $7.17M.
When is Kelyniam Global Inc’s upcoming earnings report date?
Kelyniam Global Inc’s upcoming earnings report date is Aug 17, 2026 which is in 26 days.
How were Kelyniam Global Inc’s earnings last quarter?
Kelyniam Global Inc released its earnings results on May 19, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kelyniam Global Inc overvalued?
According to Wall Street analysts Kelyniam Global Inc’s price is currently Overvalued.
Does Kelyniam Global Inc pay dividends?
Kelyniam Global Inc does not currently pay dividends.
What is Kelyniam Global Inc’s EPS estimate?
Kelyniam Global Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kelyniam Global Inc have?
Kelyniam Global Inc has 50,123,430 shares outstanding.
What happened to Kelyniam Global Inc’s price movement after its last earnings report?
Kelyniam Global Inc reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.571%.
Which hedge fund is a major shareholder of Kelyniam Global Inc?
Currently, no hedge funds are holding shares in KLYG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kelyniam Global Inc
Kelyniam Global, Inc. operates as a medical device manufacturer, providing specialized solutions for patients. The company creates custom prosthetics using computer-aided design (CAD) and manufacturing (CAM) processes, employing advanced medical-grade polymers. Additionally, Kelyniam develops, produces, and supplies specific cranial and craniofacial fixation screws, crucial for the reconstruction of skull and facial structures. Its clientele encompasses health systems, hospitals, sales representatives, surgeons, insurance providers (payors), and individual patients. Established in 2005, the company was originally named Ketner Global Investments, Inc., rebranding to Kelyniam Global, Inc. in December 2007. Kelyniam Global is based in Collinsville, Connecticut.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors